DOCSLIB.ORG

Supplementary Figure Legends

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1 Supplementary Figure legends 2 Supplementary Figure 1. 3 Experimental workflow. 4 5 Supplementary Figure 2. 6 IRF9 binding to promoters. 7 a) Verification of mIRF9 antibody by site-directed ChIP. IFNβ-stimulated binding of IRF9 to 8 the ISRE sequences of Mx2 was analyzed using BMDMs of WT and Irf9−/− (IRF9-/-) mice. 9 Cells were treated with 250 IU/ml of IFNβ for 1.5h. Data represent mean and SEM values of 10 three independent experiments. P-values were calculated using the paired ratio t-test (*P ≤ 11 0.05; **P ≤ 0.01, ***P ≤ 0.001). 12 b) Browser tracks showing complexes assigned as STAT-IRF9 in IFNγ treated wild type 13 BMDMs. Input, STAT2, IRF9 (scale 0-200). STAT1 (scale 0-150). 14 15 Supplementary Figure 3. 16 Experimental system for BioID. 17 a) Kinetics of STAT1, STAT2 and IRF9 synthesis in Raw 264.7 macrophages and wild type 18 BMDMs treated with 250 IU/ml as indicated. Whole-cell extracts were tested in western blot 19 for STAT1 phosphorylation at Y701 and of STAT2 at Y689 as well as total STAT1, STAT2, 20 IRF9 and GAPDH levels. The blots are representative of three independent experiments. b) 21 Irf9-/- mouse embryonic fibroblasts (MEFs) were transiently transfected with the indicated 22 expression vectors, including constitutively active IRF7-M15. One day after transfection, 23 RNA was isolated and Mx2 expression determined by qPCR. c) Myc-BirA*-IRF9 transgenic 24 Raw 264.7 were treated with increasing amounts of doxycycline (dox) (0,2µg/ml, 0,4µg/ml, 25 0,6µg/ml, 0,8µg/ml, 1mg/ml) and 50µM biotin. Whole-cell extracts were collected and tested 26 in western blot for levels of IRF9, MYC, and GAPDH. Biotinylated IRF9 was visualized via 27 HRP-coupled streptavidin. d) Stat2-/- MEFs were transiently transfected with the indicated 28 expression vectors, including constitutively active IRF7-M15. One day after transfection, 29 RNA was isolated and Mx2 expression was determined by qPCR. e) Myc-BirA*-STAT2 30 transgenic Raw 264.7 macrophages were treated with increasing amounts of doxycycline as 31 in f) and 50µM biotin. Whole-cell extracts were collected and tested in western blot for levels 32 of STAT2, MYC, and GAPDH. Biotinylated STAT2 was visualized via HRP-coupled 33 streptavidin. 34 35 Supplementary Figure 4. 36 IRF9 and STAT2 interactome 37 a), b) IRF9 or STAT2 interactors, either pre-associated or after IFN-β or IFN-γ treatment, 38 were identified by streptavidin affinity purification and mass spectrometry. Proteins that 39 displayed a threefold enrichment (in two biological replicates) in the samples of interest 40 compared to the ligase control were counted as hits and are shown in the heatmaps. 41 c) Multi-scatter plot of LFQ-Intensities, displaying Pearson-correlation of each biological 42 replicate. 43 44 Supplementary table 1. 45 Genes bound by STAT1, STAT2-IRF9 and ISGF3 transcription factor complexes. 46 47 Supplementary table 2. 48 PRM analysis, mass spectrometry analysis and list of interactors. 49 50 Supplementary table 3. 51 RT-qPCR and ChIP primer sequences. 52 53 Supplementary Figure 1 1) Expression analysis RNA-seq analysis No treatment Steady state IFN-I (2h) WT mRNA IRF9 -/- IFNg (2h) 2) Transcription factor complexes ChIP-seq analysis No treatment Steady state STAT1 IFN-I (1.5h) STAT2 IRF9 WT IRF9 -/- IFNg (1.5h) peak coincidence BioID analysis biotin affynity capture No treatment mass spec Steady state tryptic digest + Dox + Bio IFN-I (1.5h) N STAT2 C STAT2 STAT2 BirA* Raw 264.7 abundance rel. ~10nm IFNg (1.5h) m/z biotin affynity capture No treatment tryptic digest mass spec Steady state + Dox + Bio IFN-I (1.5h) N IRF9 C IRF9 IRF9 BirA* Raw 264.7 abundance rel. ~10nm IFNg (1.5h) m/z Distal proteins Vicinal proteins Interacting proteins N-terminal BirA* Covalently bound biotin Affinity capture cell lysates oligonucleotide affinity capture detection via western blot bioTEG STAT2 STAT1 IRF9 ISRE No treatment Steady state cell lysates immuno precipitation IFN-I (1.5h) Raw 264.7 STAT2 STAT1 IRF9 Supplementary Figure 1 1) Expression analysis RNA-seq analysis No treatment Steady state IFN-I (2h) WT mRNA IRF9 -/- IFNg (2h) 2) Transcription factor complexes ChIP-seq analysis No treatment Steady state STAT1 IFN-I (1.5h) STAT2 IRF9 WT IRF9 -/- IFNg (1.5h) peak coincidence BioID analysis biotin affynity capture No treatment mass spec Steady state tryptic digest + Dox + Bio IFN-I (1.5h) N STAT2 C STAT2 STAT2 BirA* Raw 264.7 abundance rel. ~10nm IFNg (1.5h) m/z biotin affynity capture No treatment tryptic digest mass spec Steady state + Dox + Bio IFN-I (1.5h) N IRF9 C IRF9 IRF9 BirA* Raw 264.7 abundance rel. ~10nm IFNg (1.5h) m/z Distal proteins Vicinal proteins Interacting proteins N-terminal BirA* Covalently bound biotin Affinity capture cell lysates oligonucleotide affinity capture detection via western blot bioTEG STAT2 STAT1 IRF9 ISRE No treatment Steady state cell lysates immuno precipitation IFN-I (1.5h) Raw 264.7 STAT2 STAT1 IRF9 Supplementary Figure 2 a IRF9 binding to Mx2 ISRE 0.6 * * WT IRF9-/- 0.4 % of input % 0.2 0.0 untreated IFN-β b Input S1 IFN-γ WT S1 IFN-γ IRF9-/- S2 IFN-γ WT S2 IFN-γ IRF9-/- IRF9 IFN-γ WT Treml2 Tarm1 Cish Gm4841 Supplementary Figure 3 a Raw 267.4 BMDMs IFN-β IFN-β 0 0.5 1.5 4 0 0.51.5 4 tSTAT2 tSTAT2 pSTAT2 pSTAT2 tSTAT1 tSTAT1 pSTAT1 pSTAT1 IRF9 IRF9 GAPDH GAPDH b c Mx2 mRNA expression 50 Dox - + + + + + - + + + + + 40 Biotin - - - - - - + + + + + + ← myc-BirA*IRF9 30 strep IRF9 ← myc-BirA*IRF9 20 ← endog. IRF9 fold induction fold myc 10 0 GAPDH k 9 F moc IR 7-M15 F IR myc-BirA* IRF7-M15 + myc-BirA*IRF9 d e Dox - + + + + + - + + + + + Mx2 mRNA expression Biotin - - - - - - + + + + + + 100 strep ←myc-BirA*STAT2 80 ← STAT1 60 STAT2 ←myc-BirA*STAT2 40 ←endog. STAT2 fold induction fold 20 myc 0 Tubulin k 2 moc 7-M15 F IR myc-BirA*STAT2 IRF7-M15 + myc-BirA*STAT Supplementary Figure 4 a Intensity LFQ intensity IRF9 (B) LFQ intensity IRF9 IFN-β (B) LFQ intensity IRF9 IFN-γ (A) LFQ intensity IRF9 (A) LFQ intensity IRF9 IFN-β (A) LFQ intensity IRF9 IFN-γ (B) LFQ intensity myc (A) myc intensity LFQ LFQ intensity myc (A) myc intensity LFQ LFQ intensity myc (B) myc intensity LFQ LFQ intensity myc (A) myc intensity LFQ LFQ intensity myc (B) myc intensity LFQ LFQ intensity myc (B) myc intensity LFQ 16 32 Irf9 Irf9 Irf9 Znf148 Txnl1 2210010C04Rik 2210010C04Rik Txnl1 Txnl1 Chd1 Chd1 Chd1 2210010C04Rik Baz1a Zfp384 Zfp384 Mef2d Ep400 Ep400 Ppm1g Mef2d Zeb2 Baz1a Stat2 Ppm1g Mef2d Yy1 Fli1 Ppm1g Sub1 Slx4 Fli1 AU019823 Leng8 Snrnp70 Taf1 Ep400 Mast1 Parp1 Zfp384 Gtf2e1 Leng8 Slx4 Ccnt1 Ccnt1 Fli1 Sugp1 Gtf2e1 Leng8 Taf1 Cwc15 Hivep3 Sugp1 Taf1 Chaf1b Sugp1 Parp1 Slx4 Arid1a Cwc15 Hivep3 Taf2 Hivep3 Parp1 Champ1 Yy1 Mast1 Smarcc1 Stat2 Ccnt1 Hmgn2 Taf9 Taf9 Ctcf Snrnp70 Cbx3 Aldh9a1 Chaf1b Taf9 Gtf2i Cbx3 Gtf2i Gnl2 Ikzf1 Champ1 Gnl2 Hdgf Fip1l1 Cbx3 Ctcf Alyref Atic Elf2 Gff2e1 Ikzf1 Jmjd1c Arid1a Gnl2 Chd4 Champ1 Elf2 Mki67 Elf2 Acta1 Chd4 Jmjd1c Zfp62 Mki67 Chd4 Brd4 Zfp62 Mki67 Hp1bp3 Jmjd1c Zfp62 Baz1b Dsp Numa1 Numa1 Brd4 Hp1bp3 Baz1b Hcfc1 Hp1bp3 Chd8 Chaf1 Wdhd1 Smchd1 Ptma Znf148 Numa1 Pes1 Pes1 Baz1b Brd4 Ptma Wdhd1 Smchd1 Znf148 Ddx42 Tcerg1 Chd8 Smchd1 Rif1 Ptma Chd8 Chaf1a Pcnp Ca2 Trim28 Zbtb33 Rif1 Rif1 Trim28 Trim28 Set Set Smarca5 Smarca5 Zbtb33 Set Zbtb33 Hist1h1a Hist1h1a Hist1h1a Tpx2 Tpx2 Tpx2 Smarca5 Yeats2 Yeats2 Adnp Adnp Yeats2 Kdm3b Cux1 Cux1 Nasp Hmgb1 Adnp Cux1 Nucks1 Nucks1 Nucks1 b LFQ intensity STAT2 (B) LFQ intensity STAT2 IFN-β (B) LFQ intensity STAT2 LFQ intensity STAT2 (A) LFQ intensity STAT2 IFN-β (A) LFQ intensity STAT2 LFQ intensity myc (A) myc intensity LFQ (A) myc intensity LFQ LFQ intensity myc (B) myc intensity LFQ LFQ intensity myc (B) myc intensity LFQ LFQ intensity STAT2 IFN-γ (B) LFQ intensity STAT2 LFQ intensity STAT2 IFN-γ (A) LFQ intensity STAT2 LFQ intensity myc (A) myc intensity LFQ LFQ intensity myc (B) myc intensity LFQ Acta1 H2afv Ckb Cs Hmgn2 Mtco2 Acaa1a Atp50 Atp50 Ckb AU019823 Srsf5 Mast1 Atp5h Cdc42 Taf2 Aldh9a1 Rab7a Polr1d Hmgn2 Txn Snrnp70 Txnl1 Aldh9a1 Ep400 Atic Syncrip Atp50 Psma1 Irf9 Hmgn2 Actr2 Snrnp70 Ckb Snrnp70 Parp1 Ncf1 Atic Cyb5r3 Trap1 Cbx3 Aldh9a1 AU019823 A430005L14Rik Atic Lmna AU019823 Lgals3 Tkt Cyb5r3 Atp5b Cyb5r3 S100a4 Akr1b1 Dbt Fabp5 Atp5b Mdh1 Dsp Cct2 Arhgdia Srsf1 Hist1h1e Hist1h1e Hmgb1 Nme1 S100a4 Got2 S100a4 Rps10 Rps19 2210010C04Rik Hist1h1e Ppia Stat2 Gapdh Stat2 Stat2 Stat1 Stat1 Stat1 c 0.9920 0.9857 0.9858 LFQ intensity IRF9 (B) IRF9 intensity LFQ LFQ intensity IRF9 IFN-β (Β) IFN-β IRF9 intensity LFQ LFQ intensityIRF9 IFN-γ (Β) IFN-γ intensityIRF9 LFQ LFQ intensity IRF9 (A) LFQ intensity IRF9 IFN-β (A) LFQ intensity IRF9 IFN-γ (Β) 0.9764 0.9683 0.9885 LFQ intensity STAT2 (B) STAT2 intensity LFQ LFQ intensity STAT2 IFN-β (Β) IFN-β STAT2 intensity LFQ LFQ intensityIRF9 IFN-γ (Β) IFN-γ intensityIRF9 LFQ LFQ intensity STAT2 (A) LFQ intensity STAT2 IFN-β (A) LFQ intensity STAT2 IFN-γ (Β) 0.9787 LFQ intensity myc (B) myc intensity LFQ LFQ intensity myc (A) Supplementary Figure 3 a Raw 267.4 BMDMs IFN-β IFN-β 0 0.5 1.5 4 0 0.51.5 4 tSTAT2 tSTAT2 pSTAT2 pSTAT2 tSTAT1 tSTAT1 pSTAT1 pSTAT1 IRF9 IRF9 GAPDH GAPDH b c Mx2 mRNA expression 50 Dox - + + + + + - + + + + + 40 Biotin - - - - - - + + + + + + ← myc-BirA*IRF9 30 strep IRF9 ← myc-BirA*IRF9 20 ← endog.
Recommended publications
  • Hippo/YAP Signaling Pathway: a Promising Therapeutic Target In

    Hippo/YAP Signaling Pathway: a Promising Therapeutic Target In

    Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer, Franck Verrecchia To cite this version: Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer, Franck Verrecchia. Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?. Can- cers, MDPI, 2020, 12 (3), pp.645. 10.3390/cancers12030645. inserm-03004096 HAL Id: inserm-03004096 https://www.hal.inserm.fr/inserm-03004096 Submitted on 13 Nov 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. cancers Review Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer and Franck Verrecchia * INSERM, UMR1238, Bone Sarcoma and Remodeling of Calcified Tissues, Nantes University, 44035 Nantes, France; [email protected] (S.M.); geoff[email protected] (G.D.); [email protected] (F.R.); [email protected] (B.B.-L.-R.) * Correspondence: [email protected]; Tel.: +33-244769116 Received: 4 February 2020; Accepted: 7 March 2020; Published: 10 March 2020 Abstract: Osteosarcoma and Ewing sarcoma are the most prevalent bone pediatric tumors.
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
  • FLI1 Gene Fli-1 Proto-Oncogene, ETS Transcription Factor

    FLI1 Gene Fli-1 Proto-Oncogene, ETS Transcription Factor

    FLI1 gene Fli-1 proto-oncogene, ETS transcription factor Normal Function The FLI1 gene provides instructions for making the FLI protein, which controls the activity (transcription) of genes. Transcription is the first step in the process of producing proteins. The FLI protein is part of a group of related proteins, called the Ets family of transcription factors, that control transcription. The FLI protein attaches (binds) to certain regions of DNA and turns on (activates) the transcription of nearby genes. The proteins produced from these genes control many important cellular processes, such as cell growth and division (proliferation), maturation (differentiation), and survival. The FLI protein is found primarily in blood cells and is thought to regulate their development. Health Conditions Related to Genetic Changes Ewing sarcoma Mutations involving the FLI1 gene cause a type of cancerous tumor known as Ewing sarcoma. These tumors develop in bones or soft tissues such as nerves and cartilage. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor, and Askin tumor. The mutations that cause these tumors are acquired during a person's lifetime and are present only in the tumor cells. This type of genetic change, called a somatic mutation, is not inherited. The most common mutation that causes Ewing sarcoma is a rearrangement (translocation) of genetic material between chromosome 11 and chromosome 22. This translocation, written as t(11;22), fuses part of the FLI1 gene on chromosome 11 with part of another gene called EWSR1 on chromosome 22, creating an EWSR1/FLI1 fusion gene.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Functional Characterization of the New 8Q21 Asthma Risk Locus

    Functional Characterization of the New 8Q21 Asthma Risk Locus

    Functional characterization of the new 8q21 Asthma risk locus Cristina M T Vicente B.Sc, M.Sc A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2017 Faculty of Medicine Abstract Genome wide association studies (GWAS) provide a powerful tool to identify genetic variants associated with asthma risk. However, the target genes for many allergy risk variants discovered to date are unknown. In a recent GWAS, Ferreira et al. identified a new association between asthma risk and common variants located on chromosome 8q21. The overarching aim of this thesis was to elucidate the biological mechanisms underlying this association. Specifically, the goals of this study were to identify the gene(s) underlying the observed association and to study their contribution to asthma pathophysiology. Using genetic data from the 1000 Genomes Project, we first identified 118 variants in linkage disequilibrium (LD; r2>0.6) with the sentinel allergy risk SNP (rs7009110) on chromosome 8q21. Of these, 35 were found to overlap one of four Putative Regulatory Elements (PREs) identified in this region in a lymphoblastoid cell line (LCL), based on epigenetic marks measured by the ENCODE project. Results from analysis of gene expression data generated for LCLs (n=373) by the Geuvadis consortium indicated that rs7009110 is associated with the expression of only one nearby gene: PAG1 - located 732 kb away. PAG1 encodes a transmembrane adaptor protein localized to lipid rafts, which is highly expressed in immune cells. Results from chromosome conformation capture (3C) experiments showed that PREs in the region of association physically interacted with the promoter of PAG1.
  • Downloaded from JASPAR (JASPAR ID: MA0527.1) Across All Identified Peaks Using the Matrix-Scan Module from RSAT [20]

    Downloaded from JASPAR (JASPAR ID: MA0527.1) Across All Identified Peaks Using the Matrix-Scan Module from RSAT [20]

    bioRxiv preprint doi: https://doi.org/10.1101/585653; this version posted March 24, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. ZBTB33 (Kaiso) methylated binding sites are associated with primed heterochromatin Quy Xiao Xuan Lin1, Khadija Rebbani1, Sudhakar Jha1,2, Touati Benoukraf1,3* 1Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore 2Department of Biochemistry, National University of Singapore, Singapore, Singapore 3Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada *Correspondence to: Touati Benoukraf, Ph.D. Faculty of Medicine, Discipline of Genetics Cancer Science Institute of Singapore Craig L. Dobbin Genetics Research Centre National University of Singapore Room 5M317 Centre for Translational Medicine, Memorial University of Newfoundland 14 Medical Drive, #12-01 St. John's, NL A1B 3V6 Singapore 117599 Canada Phone: +1 (709) 864-6671 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/585653; this version posted March 24, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Background: ZBTB33, also known as Kaiso, is a member of the zinc finger and BTB/POZ family. In contrast to many transcription factors, ZBTB33 has the ability to bind both a sequence-specific consensus and methylated DNA.
  • Primary Driver Mutations in GTF2I Specific to the Development Of

    Primary Driver Mutations in GTF2I Specific to the Development Of

    cancers Article Primary Driver Mutations in GTF2I Specific to the Development of Thymomas Rumi Higuchi 1, Taichiro Goto 1,* , Yosuke Hirotsu 2 , Yujiro Yokoyama 1, Takahiro Nakagomi 1, Sotaro Otake 1, Kenji Amemiya 2,3, Toshio Oyama 3, Hitoshi Mochizuki 2 and Masao Omata 2,4 1 Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi 400-8506, Japan; [email protected] (R.H.); [email protected] (Y.Y.); [email protected] (T.N.); [email protected] (S.O.) 2 Genome Analysis Center, Yamanashi Central Hospital, Yamanashi 400-8506, Japan; [email protected] (Y.H.); [email protected] (K.A.); [email protected] (H.M.); [email protected] (M.O.) 3 Department of Pathology, Yamanashi Central Hospital, Yamanashi 400-8506, Japan; [email protected] 4 Department of Gastroenterology, The University of Tokyo Hospital, Tokyo 113-8655, Japan * Correspondence: [email protected]; Tel.: +81-55-253-7111 Received: 16 June 2020; Accepted: 22 July 2020; Published: 24 July 2020 Abstract: Thymomas are rare mediastinal tumors that are difficult to treat and pose a major public health concern. Identifying mutations in target genes is vital for the development of novel therapeutic strategies. Type A thymomas possess a missense mutation in GTF2I (chromosome 7 c.74146970T>A) with high frequency. However, the molecular pathways underlying the tumorigenesis of other thymomas remain to be elucidated. We aimed to detect this missense mutation in GTF2I in other thymoma subtypes (types B). This study involved 22 patients who underwent surgery for thymomas between January 2014 and August 2019.
  • Transcriptome Sequencing and Genome-Wide Association Analyses Reveal Lysosomal Function and Actin Cytoskeleton Remodeling in Schizophrenia and Bipolar Disorder

    Transcriptome Sequencing and Genome-Wide Association Analyses Reveal Lysosomal Function and Actin Cytoskeleton Remodeling in Schizophrenia and Bipolar Disorder

    Molecular Psychiatry (2015) 20, 563–572 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder Z Zhao1,6,JXu2,6, J Chen3,6, S Kim4, M Reimers3, S-A Bacanu3,HYu1, C Liu5, J Sun1, Q Wang1, P Jia1,FXu2, Y Zhang2, KS Kendler3, Z Peng2 and X Chen3 Schizophrenia (SCZ) and bipolar disorder (BPD) are severe mental disorders with high heritability. Clinicians have long noticed the similarities of clinic symptoms between these disorders. In recent years, accumulating evidence indicates some shared genetic liabilities. However, what is shared remains elusive. In this study, we conducted whole transcriptome analysis of post-mortem brain tissues (cingulate cortex) from SCZ, BPD and control subjects, and identified differentially expressed genes in these disorders. We found 105 and 153 genes differentially expressed in SCZ and BPD, respectively. By comparing the t-test scores, we found that many of the genes differentially expressed in SCZ and BPD are concordant in their expression level (q ⩽ 0.01, 53 genes; q ⩽ 0.05, 213 genes; q ⩽ 0.1, 885 genes). Using genome-wide association data from the Psychiatric Genomics Consortium, we found that these differentially and concordantly expressed genes were enriched in association signals for both SCZ (Po10 − 7) and BPD (P = 0.029). To our knowledge, this is the first time that a substantially large number of genes show concordant expression and association for both SCZ and BPD. Pathway analyses of these genes indicated that they are involved in the lysosome, Fc gamma receptor-mediated phagocytosis, regulation of actin cytoskeleton pathways, along with several cancer pathways.
  • Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early

    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
  • Accompanies CD8 T Cell Effector Function Global DNA Methylation

    Accompanies CD8 T Cell Effector Function Global DNA Methylation

    Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer, Benjamin G. Barwick, Benjamin A. Youngblood, Rafi Ahmed and Jeremy M. Boss This information is current as of October 1, 2021. J Immunol 2013; 191:3419-3429; Prepublished online 16 August 2013; doi: 10.4049/jimmunol.1301395 http://www.jimmunol.org/content/191/6/3419 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130139 Material 5.DC1 References This article cites 81 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/191/6/3419.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer,* Benjamin G. Barwick,* Benjamin A. Youngblood,*,† Rafi Ahmed,*,† and Jeremy M.
  • Whole Genome Comparative Genomic Hybridization of Ewing Sarcoma Indicates Cytoskeleton, Migration and Protein Trafficking †

    Whole Genome Comparative Genomic Hybridization of Ewing Sarcoma Indicates Cytoskeleton, Migration and Protein Trafficking †

    Proceedings Whole Genome Comparative Genomic Hybridization of Ewing Sarcoma Indicates Cytoskeleton, Migration and Protein Trafficking † Burçin Baran 1, Safiye Aktaş 1,*, Hülya Tosun 1,2, Gülden Diniz 1,2, Yasemin Çakır 1,2, Tekincan Çağrı Aktaş 1, Zekiye Altun 1 and Nur Olgun 1 1 Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey; [email protected] (B.B.); [email protected] (H.T.); [email protected] (G.D.); [email protected] (Y.Ç.); [email protected] (T.Ç.A.); [email protected] (Z.A.); [email protected] (N.O.) 2 Dr.Behcet Uz Children’s Research Hospital, Izmir 35210, Turkey * Correspondence: [email protected] † Presented at the 2nd International Cell Death Research Congress, Izmir, Turkey, 1–4 November 2018. Published: 5 December 2018 Abstract: Ewing sarcoma is a bone and soft tissue tumor either neuroectodermal or mesenchymal originated and affecting children and adolescents. In the present study, we aimed to find out prognostic and predictive biomarkers for Ewing sarcoma. Hence, we examined the copy number alterations (and related possible genes) among ten Ewing sarcoma patient samples and possible associations with the clinical outcome. DNA extraction from formalin fixed paraffin embedded archive tissues was performed. Whole genome Comparative Genomic Hybridization (CGH) was performed by NimbleGen and recorded as single Panel Rainbow through chromosomes 1–22, X and Y. Data was interpreted by SignalMap software and genetic regions matching the deletion or amplification loci were recorded. The mean age of the patients was 8.6 years. Three of the cases were male, while seven were female. According to CGH analysis, the most common DNA copy number alterations were found in SLIT-ROBO Rho GTPase activating protein (srGAP2), RANBP2 like GRIP domain (RGPD5), nephrocystin 1 (NPHP1), GTF2I repeat domain containing 2 (GTF2IRD2), pyridoxal dependent decarboxylase domain containing 1 (PXDC1), which were found down- regulated among 7 of 10 patients.
  • CARBOPLATIN and PACLITAXEL a Dissertation SUBMITTED

    CARBOPLATIN and PACLITAXEL a Dissertation SUBMITTED

    PHARMACOGENOMICS OF CHEMOTHERAPEUTIC AGENTS: CARBOPLATIN AND PACLITAXEL A Dissertation SUBMITTED TO THE FACULTY OF UNIVERSITY OF MINNESOTA BY Taraswi Mitra Ghosh IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Dr. Jatinder K. Lamba May 2017 © Taraswi Mitra Ghosh, 2017 ACKNOWLEDGEMENTS At this special moment when I have reached the concluding stages of my Doctoral research and am ready to embark upon another voyage in my scientific career, I would like to take the opportunity to acknowledge the contributions of the people who have shaped up my life and career. First and foremost, I would like to thank Almighty God for giving me the strength to overcome all the challenges, for giving me the motivation to learn and to acquire knowledge. I would like to thank Dr. Jatinder Lamba, my adviser. I have learned a lot from her and am extremely thankful to her. She has helped me develop my scientific temper and inquisitive thinking. I would like to express my sincere gratitude towards my committee members. Dr. Mark Kirstein, my committee chair, has been a constant support. He has helped me develop my concepts in Pharmacokinetics. His insightful questions during our discussions have encouraged me to think deep and broaden my knowledge base. Dr. Angela Birnbaum, my committee member and DGS, has always been a strong support. Working with her was a very nice and cherishable experience for me. She has provided me the confidence to undertake independent projects- an experience which I am sure will be helpful in my future as a Scientist. I would like to thank Dr.